Richard S Geary

This inventor holds 15 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 12 EPO patents. Top assignees: Isis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Carlsbad. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard S Geary. Retrieved from https://idiyas.com/inventor/richard-s-geary

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 13)

% Patents Active = 53.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 160(Granted Patents)

Company Filing History:

10 out of 1,035

Isis Pharmaceuticals, Inc.

patents

4 out of 288

Ionis Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410430 - Modulating apolipoprotein (A) expression (2025-09-09),

2. 11319536 - Modulating apolipoprotein (a) expression (2022-05-03),

3. 10557137 - Modulating apolipoprotein (a) expression (2020-02-11),

4. 9617540 - Compounds and methods for modulating gene expression (2017-04-11),

5. 9347061 - Administering antisense oligonucleotides complementary to human apolipoprotein B (2016-05-24),

6. 9045754 - Short antisense compounds with gapmer configuration (2015-06-02),

7. 8969316 - Compounds and methods for modulating expression of DGAT2 (2015-03-03),

8. 8673871 - Compounds and methods for modulating expression ApoB (2014-03-18),

9. 8586554 - Compounds and methods for modulating expression of PTP1B (2013-11-19),

10. 8372967 - Compounds and methods for modulating expression of GCCR (2013-02-12),

11. 8362232 - Compounds and methods for modulating expression of SGLT2 (2013-01-29),

12. 8188059 - Compounds and methods for modulating expression of GCGR (2012-05-29),

13. 8143230 - Compounds and methods for modulating expression of PCSK9 (2012-03-27),

14. 7576067 - Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption (2009-08-18),

15. 6083923 - Liposomal oligonucleotide compositions for modulating RAS gene expression (2000-07-04),

Title: The Innovative Mind of Richard S. Geary

Introduction: Richard S. Geary, an accomplished inventor based in Carlsbad, California, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 14 patents, Richard has demonstrated his dedication to advancing scientific understanding and developing innovative solutions that address pressing health concerns.

Latest Patents: One of Richard's notable patents focuses on modulating apolipoprotein (a) expression. The invention involves oligomeric compounds designed with conjugate groups targeting apolipoprotein (a) [apo(a)]. In this patent, certain embodiments describe how these compounds are conjugated to N-Acetylgalactosamine. The oligomeric compounds aim to decrease apo(a) levels, thereby offering potential treatment options for various diseases, disorders, or conditions associated with apo(a) and/or Lp(a), which include inflammatory, cardiovascular, and metabolic issues. These innovative compounds may prove essential for individuals needing to manage their health effectively.

Career Highlights: Throughout his career, Richard has been associated with prominent companies in the biotechnology sector, including Isis Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. His work has not only broadened his expertise but also contributed to significant advancements in drug development and therapeutic applications. Richard's focus on modulating apolipoprotein expression reflects his commitment to addressing critical health issues through innovative research.

Collaborations: Richard has had the opportunity to collaborate with esteemed colleagues, including Sanjay Bhanot and Robert McKay. These collaborations highlight the synergy between talented professionals in the biotech field, fostering an environment where innovative ideas can flourish and contribute to groundbreaking inventions.

Conclusion: Richard S. Geary's journey as an inventor underscores the importance of innovation in biotechnology. With his extensive patent portfolio and dedication to research, he continues to pave the way for new therapeutic strategies that hold promise for improving health outcomes. As his work progresses, it is likely that Richard will remain at the forefront of scientific innovation, striving to address the complex challenges faced in the medical field.

Profile summary based on public USPTO records.